tbuckley/cabot-search huggingface dataset:
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
Journal: Clinical Cancer Research (2021)
THE ESTABLISHMENT OF A NATIONAL QUARANTINE STATION NEAR NEW YORK HARBOR.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biliary motility.
Authors: P A Grace, G J Poston, R C Williamson
Journal: Gut (1990)

The delivery ofbile to the duodenum depends on hepatic secretion of bile plus onward propulsion through the biliary tract.Biliary kinetics involve a series of complex interrelationships between gall bladder, cystic duct, common bile duct, sphincter of Oddi and upper small intestine, with control modulation by various neural and hormonal agents.The application of modern techniques to the study of biliary motility has allowed a composite physiological picture to emerge.Moreover, alterations in biliary motility are increasingly implicated in the aetiology of gall stones and postcholecystectomy symptoms.The present review examines recent developments in the understanding of biliary motility and discusses the detailed events involved in delivering bile to the duodenum.
Supporting people responding to overdoses
Authors: Charles Marks, Karla D Wagner
Journal: The Lancet Public Health (2022)

The overdose crisis continues to escalate. Providing naloxone to people at the highest risk of having or witnessing an opioid overdose is a key strategy in addressing the worsening crisis.1 An opioid overdose can be reversed with naloxone if a witness accurately identifies the medical emergency, has naloxone available, and administers it. Findings from a mathematical modelling study published by Michael Irvine and colleagues2 in The Lancet Public Health showed how much naloxone needs to be distributed in each state of the USA to ensure that naloxone can be used to reverse at least 80% of witnessed opioid overdoses.
Chronic recurrent ventricular tachycardia.
Journal: BMJ (1979)

ai Chronic recurrent ventricular tachycardia Chronic recurrent ventricular tachycardia is always a serious arrhythmia since it may deteriorate into fatal ventricular fibrillation.Chronic recurrent ventricular tachycardia at a rate of 250 beats/minute may cause syncope, but at a rate of 100-150 may not cause any symptoms.Often, but not always, a signal to serious underlying heart disease, the arrhythmia may recur or may disappear as mysteriously as it came.Treatment usually demands long-term drugs, and control may prove difficult.Chronic recurrent ventricular tachycardia may complicate ischaemic heart disease and almost any heart-muscle disease.It is more likely when the QT interval is prolonged, when both recurrence and conversion to ventricular fibrillation may be encouraged by quinidine-like antiarrhythmic drugs that further prolong repolarisation.Chronic recurrent ventricular tachycardia seems to have become more common-possibly as a result of increased survival of patients after myocardial infarction.
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Authors: Christina M Brennan, Sandeep Nadella, Xiang Zhao, Richard J Dima, Nicole Jordan-Martin, Breanna R Demestichas, Sam O Kleeman, Miriam Ferrer, Eva Carlotta von Gablenz, Nicholas Mourikis, Michael E Rubin, Harsha Adnani, Hassal Lee, Taehoon Ha, Soma Prum, Cheryl B Schleicher, Sharon S Fox, Michael G Ryan, Christina Pili, Gary Goldberg, James M Crawford, Sara Goodwin, Xiaoyue Zhang, Jonathan B Preall, Ana S H Costa, Joseph Conigliaro, Joseph R Masci, Jie Yang, David A Tuveson, Kevin J Tracey, Tobias Janowitz
Journal: Gut (2022)

Objective We assessed whether famotidine improved inflammation and symptomatic recovery in outpatients with mild to moderate COVID-19. Design Randomised, double-blind, placebo-controlled, fully remote, phase 2 clinical trial ( NCT04724720 ) enrolling symptomatic unvaccinated adult outpatients with confirmed COVID-19 between January 2021 and April 2021 from two US centres. Patients self-administered 80 mg famotidine (n=28) or placebo (n=27) orally three times a day for 14 consecutive days. Endpoints were time to (primary) or rate of (secondary) symptom resolution, and resolution of inflammation (exploratory). Results Of 55 patients in the intention-to-treat group (median age 35 years (IQR: 20); 35 women (64%); 18 African American (33%); 14 Hispanic (26%)), 52 (95%) completed the trial, submitting 1358 electronic symptom surveys. Time to symptom resolution was not statistically improved (p=0.4). Rate of symptom resolution was improved for patients taking famotidine (p&lt;0.0001). Estimated 50% reduction of overall baseline symptom scores were achieved at 8.2 days (95% CI: 7 to 9.8 days) for famotidine and 11.4 days (95% CI: 10.3 to 12.6 days) for placebo treated patients. Differences were independent of patient sex, race or ethnicity. Five self-limiting adverse events occurred (famotidine, n=2 (40%); placebo, n=3 (60%)). On day 7, fewer patients on famotidine had detectable interferon alpha plasma levels (p=0.04). Plasma immunoglobulin type G levels to SARS-CoV-2 nucleocapsid core protein were similar between both arms. Conclusions Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomised trials are required.
Neuropathic pain
Authors: Luana Colloca, Taylor Ludman, Didier Bouhassira, Ralf Baron, Anthony H. Dickenson, David Yarnitsky, Roy Freeman, Andrea Truini, Nadine Attal, Nanna B. Finnerup, Christopher Eccleston, Eija Kalso, David L. Bennett, Robert H. Dworkin, Srinivasa N. Raja
Journal: Nature Reviews Disease Primers (2017)
Association of Human Papillomavirus Vaccination With the Incidence of Squamous Cell Carcinomas of the Anus in the US
Authors: Abbey B. Berenson, Fangjian Guo, Mihyun Chang
Journal: JAMA Oncology (2022)

This cross-sectional study uses data from the US Cancer Statistics database to examine the association of human papillomavirus (HPV) vaccination with incidence of squamous cell carcinomas of the anus in a vaccine-eligible US cohort.
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors: G. Argilés, J. Tabernero, R. Labianca, D. Hochhauser, R. Salazar, T. Iveson, P. Laurent-Puig, P. Quirke, T. Yoshino, J. Taieb, E. Martinelli, D. Arnold
Journal: Annals of Oncology (2020)
From shrinking violet to English rose
Authors: W. H. Crosby
Journal: JAMA (1979)

During its era of some 33 years, chemotherapy has greatly prolonged the lives of patients with Hodgkin's disease and may even cure it, but among its ravaging side effects, unbeknown to us until now, is the destruction of sexuality. It has been recognized that some alkylating agents administered year after year in chronic leukemia (busulfan, chlorambucil) may eventually cause sterility in men. But we were unaware that the pulses of drugs used in Hodgkin's disease destroyed libido, ruining personal relations and disrupting families—this in addition to causing sterility. An unbelievable amount of human misery has been silently borne by the patients of three decades. Several years ago when Ramona M. Chapman, MD, had completed her fellowship at Scripps Clinic, she sought and was granted additional research experience at St Bartholomew's Hospital in London. She hoped to continue her studies of breast cancer, intending to investigate, among other matters, the changes
Pancreatic Cancer
Authors: Anirban Maitra, Ralph H. Hruban
Journal: Annual Review of Pathology Mechanisms of Disease (2008)

The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic and transcriptomic alterations that facilitate cell cycle deregulation, cell survival, invasion, and metastases. Pancreatic cancers do not arise de novo, and three distinct precursor lesions have been identified. Experimental models of pancreatic cancer have been developed in genetically engineered mice, which recapitulate the multistep progression of the cognate human disease. Although the putative cell of origin for pancreatic cancer remains elusive, minor populations of cells with stem-like properties have been identified that appear responsible for tumor initiation, metastases, and resistance of pancreatic cancer to conventional therapies.
Stem cell therapy for muscular dystrophies
Authors: Stefano Biressi, Antonio Filareto, Thomas A. Rando
Journal: Journal of Clinical Investigation (2020)

Muscular dystrophies are a heterogeneous group of genetic diseases, characterized by progressive degeneration of skeletal and cardiac muscle. Despite the intense investigation of different therapeutic options, a definitive treatment has not been developed for this debilitating class of pathologies. Cell-based therapies in muscular dystrophies have been pursued experimentally for the last three decades. Several cell types with different characteristics and tissues of origin, including myogenic stem and progenitor cells, stromal cells, and pluripotent stem cells, have been investigated over the years and have recently entered in the clinical arena with mixed results. In this Review, we do a roundup of the past attempts and describe the updated status of cell-based therapies aimed at counteracting the skeletal and cardiac myopathy present in dystrophic patients. We present current challenges, summarize recent progress, and make recommendations for future research and clinical trials.
Collapsing Glomerulopathy
Authors: Mamdouh Albaqumi, Timothy J Soos, Laura Barisoni, Peter J Nelson
Journal: Journal of the American Society of Nephrology (2006)

Collapsing glomerulopathy (CG) has become an important cause of ESRD. First delineated from other proteinuric glomerular lesions in the 1980s, CG is now recognized as a common, distinct pattern of proliferative parenchymal injury that portends a rapid loss of renal function and poor responses to empiric therapy. Notwithstanding, the rise in disorders that are associated with CG, the identification of the first susceptibility genes for CG, the remarkable increase in murine modeling of CG, and promising preclinical testing of new therapeutic strategies suggest that the outlook for CG as a poorly understood and therapeutically resistant renal disease is set to change in the future. This focused review highlights recent advances in research into the pathogenesis and treatment of CG.
Serendipity in clinical investigation
Authors: J. E. Howard
Journal: JAMA (1969)

Serendipity is one of my favorite words. Not only is it euphonious but its meaning carries overtones and innuendos of precise yet ephemeral nature, as so many French words do, and so few do in our own language. The word was invented by Horace Walpole; but, with its wide popularity, the original meaning has often been corrupted to signify everything from accidental discovery to<i>serene stupidity</i>. Walpole's letter to Horace Mann on the derivation of the word and its meaning makes delightful reading, and I shall quote some excerpts: Serendipity, a very expressive word, which, as I have nothing better to tell you in this letter, I shall endeavor to explain to you; you will understand it better by the derivation than by the definition. I once read a silly fairy tale, called the Three Princes of Serendip: as their hignesses travelled, they were always making discoveries, by accidents and
WOMEN KEPT OUT OF SALT LAKE MEDICAL SOCIETY.
Authors: Ellen Curtis Gage
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SeqSeg: A sequential method to achieve nasopharyngeal carcinoma segmentation free from background dominance
Authors: Guihua Tao, Haojiang Li, Jiabin Huang, Chu Han, Jiazhou Chen, Guangying Ruan, Wenjie Huang, Yu Hu, Tingting Dan, Bin Zhang, Shengfeng He, Lizhi Liu, Hongmin Cai
Journal: Medical Image Analysis (2022)
Multipurposing CARs: Same engine, different vehicles
Authors: A.K.M. Nawshad Hossian, Christopher S. Hackett, Renier J. Brentjens, Sarwish Rafiq
Journal: Molecular Therapy (2022)

T cells genetically engineered to recognize and eliminate tumor cells through synthetic chimeric antigen receptors (CARs) have demonstrated remarkable clinical efficacy against B cell leukemia over the past decade. This therapy is a form of highly personalized medicine that involves genetically modifying a patient's T cells to recognize and kill cancer cells. With the FDA approval of 5 CAR T cell products, this approach has been validated as a powerful new drug in the therapeutic armamentarium against cancer. Researchers are now studying how to expand this technology beyond its use in conventional polyclonal αβ T cells to address limitations to the current therapy in cancer and applications beyond it. Considering the specific characteristics of immune cell from diverse lineages, several preclinical and clinical studies are under way to assess the advantages of CAR-redirected function in these cells and apply the lessons learned from CAR T cell therapy in cancer to other diseases.
JAMA 75 YEARS AGO
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
26. Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain
Authors: Barbara Bailus, Benjamin Pyles, Michelle McAlister, Henriette O'Geen, Sarah Lockwood, Alexa Adams, Jennifer Trang Nguyen, Abigail Yu, Robert Berman, David J. Segal
Journal: Molecular Therapy (2016)

Angelman Syndrome is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for Angelman Syndrome. However, widespread delivery of gene regulators to the brain remains challenging. Here we report an engineered zinc finger-based artificial transcription factor that, when injected intraperitoneally or subcutaneously, crossed the blood-brain barrier, and increased Ube3a expression in the brain of an adult mouse model of Angelman Syndrome. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An artificial transcription factor containing an alternative DNA-binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.
RATIONAL USE OF THE VITAMINS
Authors: W. H. B.
Journal: Annals of Internal Medicine (1944)

Editorial1 November 1944RATIONAL USE OF THE VITAMINSW. H. B.W. H. B.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-21-5-913 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen, if, and how to take vitamins, what vitamins to take, whether to take pure vitamins or crude vitamin-complexes—these are only some of the questions that today must perplex the layman and indeed the physician as well, since the latter is called upon constantly to prescribe vitamins, interpret their effects, and above all to "debunk" vitamins. If we were to accept some of the more flowery claims for the vitamins that are glibly passed out to us over the radio, we might wonder how the human race ever managed to survive to see the dawn of the twentieth century with... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1944Volume 21, Issue 5Page: 913-916KeywordsRacial and ethnic issuesVitamins ePublished: 1 December 2008 Issue Published: 1 November 1944 PDF downloadLoading ...
Authors’ correction for Euro Surveill. 2021;26(37)
Journal: Eurosurveillance (2021)

© This work is licensed under a Creative Commons Attribution 4.0 International License. Closure This is a corrected article applying to the following content: Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021
Evaluation of Statewide Restrictions on Flavored e-Cigarette Sales in the US From 2014 to 2020
Authors: Fatma Romeh M. Ali, Donna Vallone, Elizabeth L. Seaman, Jamie Cordova, Megan C. Diaz, Michael A. Tynan, Katrina F. Trivers, Brian A. King
Journal: JAMA Network Open (2022)

e-Cigarettes are the most commonly used tobacco product among US youths. Flavors are among the most cited reasons for use of e-cigarettes among youths, and therefore, some states have imposed restrictions on flavored e-cigarette sales. To our knowledge, no study has compared e-cigarette sales between states with statewide flavored e-cigarette restrictions and states without such restrictions while controlling for co-occurring events.
Aligning disaster risk reduction and climate change adaptation in the post-COP26 era
Authors: Martina Valente, Monica Trentin, Luca Ragazzoni, Francesco Barone-Adesi
Journal: The Lancet Planetary Health (2022)

The latest report of the Intergovernmental Panel on Climate Change (IPCC) shows that human activity contributes unequivocally to global warming and climate change.1 Climate change, in turn, drives the current increase in weather extremes and climate-related disasters.2 Moreover, human-induced processes, such as unplanned urbanisation, further magnify disaster risk,3 putting an increasingly large portion of the global population in danger in the years to come.
Routine Contraception
Authors: Eduard Eichner
Journal: JAMA (1961)

<h3>To the Editor:—</h3> InThe Journal, Feb. 25, page 730, Kautsky decries suppression of ovulation as a contraceptive measure. Although I do agree with him that more research is needed, I disagree with his statement that it is "loaded with danger of producing malformed children..." Can anyone compare the after-effects of sterility produced by pituitary cachexia secondary to starvation, inanition, fear, and concentration camps with pituitary suppression which is the result of balanced steroid therapy? Today's patients are not deficient in diet or in estrogenic or progestational activity. Their thyroids and adrenals are within normal limits. Moreover they are much happier, more complacent, and completely free of fear, requiring neither stimulation nor suppression of the reticular system. In addition, one should not claim that a drug which may (and occasionally does) produce toxic results on the recent conceptus is a bad drug when used properly for the suppression of ovulation